Methods of treating urothelial carcinoma using an anti-pd-1 antibody
AssigneeBristol-Myers Squibb Company
InventorMarina TSCHAIKA
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Claims15
A method for treating a subject afflicted with a urothelial carcinoma (UC) or cancer derived therefrom comprising administering to the subject an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody”).
A kit for treating a subject afflicted with a UC or a cancer derived therefrom, the kit comprising:
- (a) an amount ranging from about 4 mg to about 500 mg of an anti-PD-1 antibody or an antigen-binding portion thereof;
- and
- (b) instructions for using the PD-1 antibody in the method of any of claims 1-58.
A kit for treating a subject afflicted with a UC or a cancer derived therefrom, the kit comprising:
- (a) an amount ranging from about 4 mg to about 500 mg of an anti-PD-1 antibody or an antigen-binding portion thereof;
- (b) an amount ranging from about 4 mg to about 500 mg of a CTLA-4 antibody or an antigen-binding portion thereof;
- and
- (c) instructions for using the PD-1 antibody and the CTLA-4 antibody in the method of any of claims 2-58.
Dependencies are inferred from the claim text.